Table 2.
Meta-analysis results of the associations of decreased SIRT6 expression with clinicopathological parameters
| Clinicopathological parameter | Study Number | Overall OR (95% CI) | I2 ( P-value) |
|---|---|---|---|
| Gender (male vs female) | 9 | 0.92 (0.63–1.33) | 24.5%, 0.226 |
| Tumor differentiation (poor/moderate vs well) | 8 | 1.35 (0.68–2.67) | 77.8%, < 0.001 |
| T status (T3-4 vs T1-2) | 9 | 1.24 (0.70–2.18) | 56.7%, 0.018 |
| Lymph node metastasis (yes vs no) | 8 | 0.86 (0.55–1.36) | 58.7%, 0.010 |
| Distant metastasis (yes vs no) | 3 | 2.98 (1.59–5.57) | 0.00%, 0.694 |
| TNM stage (III-IV vs I-II) | 7 | 0.69 (0.35–1.34) | 70.6%, 0.001 |
If 95% CI value contain 1.0, it means that the 95% CI value intersect the ineffective line and the OR value was no statistical significance